The Oxford University-AstraZeneca covid vaccine is now undergoing Phase III clinical trials in Britain, Brazil, South Africa and India.
Adar Poonawalla with Professor Adrian Hill; standing next to Edward Jenner statue.
Serum Institute of India chief Adar Poonawalla remains optimistic on Oxford covid vaccine as the coronavirus pandemic claimed close to 9 lakh lives across the world. Viewed as a front-runner in the global race to deliver an effective vaccine to combat Covid-19, the Oxford University-AstraZeneca vaccine is now undergoing Phase III clinical trials in Britain, Brazil, South Africa and India.
"Proud and excited for the next few months and looking forward to the vaccine," Poonawalla tweeted.
In his tweet, Poonawalla shared photograph of standing next to the legendary Edward Jenner statue at University of Oxford, along with Professor Adrian Hill. In India, the Oxford covid vaccine is undergoing advanced trials.
The origins of the Oxford vaccine with Professor Adrian Hill; standing next to the legendary Edward Jenner statue, here at @UniofOxford. Proud and excited for the next few months and looking forward to the vaccine. pic.twitter.com/rRJVBWGV7N
— Adar Poonawalla (@adarpoonawalla) September 7, 2020
Recently, Serum Institute of India CEO Adar Poonawalla was named are among the “emerging leaders" from across the world named by Fortune in its annual list of influential people under the age of 40.
The Serum Institute is the world's largest manufacturer of vaccines by volume. And it has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of Oxford University in collaboration with British-Swedish pharma company AstraZeneca.
Professor Hill is Director of the Jenner Institute, which focuses on designing and developing vaccines for infectious diseases prevalent in developing countries.
Serum Institute of India has entered into a partnership with Gavi, The Vaccine Alliance and the Bill & Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and low- and middle-income countries.
Serum Institute of India has also entered into a supply and license with US vaccine-maker Novavax Inc for the development and commercialization of its COVID-19 vaccine candidate.
The Indian vaccine maker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the “Pandemic Period" in all countries other than those designated by the World Bank as upper-middle or high-income countries.
A new experimental Covid-19 vaccine originating from the University of Oxford has begun human trials in Australia in partnership with the Serum Institute of India, the world’s largest vaccine manufacturer.
The shot was devised by SpyBiotech, a U.K. company spun out of Oxford in 2017 by researchers who worked alongside Adrian Hill and Sarah Gilbert at the university’s Jenner Institute. (With Agency Inputs)
Source - liveMint
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
SERUM INSTITUTE OF INDIA TO PRODUCE UP TO AN ADDITIONAL 100 MILLION COVID-19 VACCINE DOSES FOR INDIA AND LOW-AND MIDDLE-INCOME COUNTRIES IN 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.